Results 121 to 130 of about 33,519 (179)
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1975 openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Experimental Hematology, 2009
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua L, Shipley, James N, Butera
openaire +2 more sources
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua L, Shipley, James N, Butera
openaire +2 more sources
Therapy of Acute Myelogenous Leukemia
Blood Reviews, 1983Over the past 10 years, there have been substantial advances in the treatment of AML. Intensive induction chemotherapy using 7-day courses of cytarabine and daunorubicin or amsacrine produce remission in 60% to 85% of patients. Median remission duration is 9 to 16 months. In some series, 20% to 40% of patients are in continuous remission for 2 years or
K A, Foon, R P, Gale
openaire +3 more sources
Acute myelogenous leukemia heteroantisera
Clinical Immunology and Immunopathology, 1980Abstract Antisera were raised in New Zealand white rabbits to acute myelogenous leukemia (AML) cells. Reactivity of the antisera against normal T lymphocytes was eliminated by pretreating the rabbits with anti-leukocyte serum (ALS) and precoating the immunizing cell with ALS.
R, Billing +4 more
openaire +2 more sources
Acute Myelogenous Leukemia in Pregnancy
Southern Medical Journal, 1984The experience with acute myelogenous leukemia treated with newer chemotherapeutic agents during pregnancy is limited. We have reported the case of a mother treated during the 24th week of pregnancy, and her infant delivered in the 29th week. At 14 months the infant is of low height and weight, but has a normal head circumference and developmental ...
E, Cantini, B, Yanes
openaire +2 more sources
Pseudohypopyon in Acute Myelogeneous Leukemia
Journal of Pediatric Ophthalmology & Strabismus, 1995ABSTRACT An 11-month-old boy presented with uniocular hypopyon, elevated intraocular pressure, and iris nodules. A differential diagnosis of physical abuse, infection, retinoblastoma, juvenile xanthogranuloma, and histiocytosis X were considered but initial physical and laboratory investigations all had normal results.
A, Ells, W N, Clarke, L P, Noel
openaire +2 more sources
Fever in Acute Myelogenous Leukemia
Clinical Pediatrics, 1982Twenty patients with acute myelocytic leukemia were observed over a period of 16.5 patient years in an attempt to identify any relationship between fever, granulocytopenia (<1000 gran ulocytes/μl), infection, and disease status. An infectious origin for fever in association with gran ulocytopenia could be established in the majority of instances ...
P D, Sadowitz, J A, Stockman
openaire +2 more sources
JAMA, 2007
TABLE OF CONTENTS I. Overview of AML: Francis Giles, MD Anderson II. Molecular Foundations of AML Pathogenesis and Pathophysiology A. Transcriptional Control of Myeloid Differentiation and Transformation: Alan Friedman, Johns Hopkins B. Myelodysplasia-Related AML: Ghulam Mufti, King's College, London, England C.
Ursula Creutzig, William G Woods
+4 more sources
TABLE OF CONTENTS I. Overview of AML: Francis Giles, MD Anderson II. Molecular Foundations of AML Pathogenesis and Pathophysiology A. Transcriptional Control of Myeloid Differentiation and Transformation: Alan Friedman, Johns Hopkins B. Myelodysplasia-Related AML: Ghulam Mufti, King's College, London, England C.
Ursula Creutzig, William G Woods
+4 more sources
Smouldering Acute Myelogenous Leukemia
Acta Medica Scandinavica, 1978ABSTRACT. Among 195 patients with variants of acute myelogenous leukemia (AML), a minimum of 11 met our criteria of smouldering AML: patients with less than 30% of blast cells plus promyelocytes in the bone marrow at the time of diagnosis who were observed without specific antileukemic therapy for a period of at least 6 months without entering a ...
S A, Evensen, P, Stavem
openaire +2 more sources
Hypocholesterolemia in acute myelogenous leukemia
European Journal of Haematology, 1988Plasma‐cholesterol concentrations were determined in 85 acute myelogenous leukemia patients. Measurements were repeated in 28 cases during remission. Mean plasmacholesterol concentration (± SD) at diagnosis was 3.95 mmol/l (± 1.29). 47 patients (55.3%) had hypocholesterolemia (< 3.87 mmoi/l).
J C, Reverter +5 more
openaire +2 more sources